Description
Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. Cyclin D3 loss has been reported in T-ALL, a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. In a mouse study, the targeted therapeutic palbociclib significantly increased the median survival of the cyclin D3 knockouts.
Cyan = gene · Slate = variant · Green = drug · Click variant to filter table
Variants (2)
| CIViC ID | Name | HGVS | Type(s) |
|---|---|---|---|
| 2747 | Amplification | ||
| 23 | Loss | loss_of_function_variant |